Some people with multiple sclerosis do live for years, even decades, with relatively mild disability and no medication. But the odds are not in favor of skipping treatment. Without disease-modifying therapy, about two-thirds of people with relapsing-remitting MS will eventually transition to a progressive form of the disease, and the median time to needing a cane is roughly 18 years from symptom onset. Whether forgoing medication is a reasonable gamble depends heavily on your specific disease profile, and even people who feel fine can have damage accumulating silently in their brain.
What Happens to Untreated MS Over Time
The clearest picture of untreated MS comes from long-term population studies that tracked patients before modern medications existed. In one of the largest, following over 800 patients for decades, 66% of people who started with relapsing-remitting MS eventually developed secondary progressive MS, where disability worsens steadily rather than in discrete relapses. After 25 years, that number climbed above 80%.
Disability milestones tell a starker story. The median time from disease onset to reaching a point where walking required a cane was 18 years. About 67% of patients eventually reached that level of disability, and nearly half progressed to needing a wheelchair. Early relapse frequency mattered enormously: people who had three or more relapses in their first two years reached the cane-required stage about 15 years after onset, while those with only one early relapse took closer to 23 years. The disease didn’t stop anyone’s life quickly, but it steadily narrowed what they could do.
The “Benign MS” Question
You may have heard that some people have “benign” MS, meaning they stay minimally disabled for a long time. This is real, but the label is slippery. Researchers typically define benign MS as having only mild disability after 10 to 15 years. By that definition, anywhere from 30% to 80% of relapsing-remitting patients qualify at the 10-year mark, depending on exactly where the cutoff is set.
The problem is that benign MS doesn’t always stay benign. In one Icelandic cohort, 91% of relapsing-remitting patients met benign criteria at 10 years, but that dropped to 69% by 20 years. Data from British Columbia showed that among people classified as benign at 10 years, only about half still qualified a decade later. The rest had progressed. So feeling good at year 10 is encouraging, but it’s not a reliable predictor of what year 20 or 30 will look like.
Silent Damage You Can’t Feel
One of the most deceptive features of MS is that the brain can sustain significant damage without obvious symptoms. Brain volume loss, or atrophy, occurs in everyone as they age, typically at a rate of 0.1% to 0.3% per year. In people with MS who are untreated, that rate jumps to roughly 0.7% per year, more than double the normal pace. This accelerated shrinkage reflects ongoing nerve damage and correlates with future cognitive problems and physical disability.
Notably, a meta-analysis found that first-generation medications like interferons and glatiramer acetate didn’t significantly slow this brain volume loss compared to no treatment. The annual rate was essentially the same, around 0.7%, whether patients took those older drugs or nothing at all. Newer, more potent therapies have shown better results on this measure, which is one reason neurologists have shifted toward recommending more effective treatments earlier in the disease course.
The Cost of Waiting
Delaying treatment carries measurable consequences. In a study of people diagnosed with MS before age 18, those who started medication more than two years after symptom onset had a 2.5 times greater risk of reaching moderate disability compared to those treated within two years. For every additional year of delay, the risk of reaching that disability level increased by 17%, and the chance of experiencing meaningful improvement dropped by 10%.
This concept of a “window of opportunity” reflects what researchers understand about MS biology. In the earlier, inflammatory phase of the disease, medications can reduce the immune attacks that cause damage. Once the disease transitions to a progressive phase driven more by neurodegeneration, those same medications become far less effective. Waiting until you feel worse to start treatment may mean missing the period when treatment could have done the most good.
The 2024 revisions to the McDonald diagnostic criteria reflect this urgency. The updated criteria now allow MS to be diagnosed earlier, including in some cases where people have MRI findings typical of MS but no symptoms yet. The rationale is straightforward: if the biology confirms the disease is present, earlier intervention protects the brain.
Who Might Reasonably Monitor Without Treatment
There are narrow circumstances where a neurologist may consider watchful waiting rather than immediate medication. This typically applies to people at the lowest end of the risk spectrum: those with very few lesions, no spinal cord involvement, and infrequent or mild relapses. Even clinical guidelines note, however, that once a biological diagnosis of MS is confirmed, the philosophical default should be treatment.
Risk factors that push away from watchful waiting include being male (men tend to progress faster), younger age at onset, lesions in the spinal cord or brainstem, positive spinal fluid markers, and elevated levels of a protein called neurofilament light chain that signals active nerve damage. If any of these apply to you, the case for starting treatment is stronger. If you’re considering forgoing medication, your neurologist would likely recommend close monitoring with regular MRI scans and neurological exams to catch any silent progression early.
What Lifestyle Changes Can and Can’t Do
Lifestyle interventions genuinely help with MS, but they are not substitutes for disease-modifying therapy. Regular physical activity has been shown to benefit relapse rates, slow brain atrophy, and reduce disability progression. Exercise works partly by shifting the body’s inflammatory balance in a favorable direction, and it improves fatigue, mood, and mobility in ways that medications don’t directly address.
Vitamin D deficiency is common in people with MS, and low levels are associated with higher relapse risk and faster disease worsening. Maintaining adequate vitamin D through supplementation or sun exposure is a reasonable, low-cost measure. Omega-3 fatty acids from fish oil have shown benefits in reducing inflammatory markers and may modestly lower relapse rates, based on a systematic review of over 5,500 studies. Plant-based diets low in saturated fat, like the Overcoming MS diet or the Swank diet, are popular in the MS community, though researchers have not identified any single dietary approach that definitively alters the disease course.
The honest summary: a healthy lifestyle can reduce inflammation, improve how you feel day to day, and may slow some aspects of disease activity. But no combination of diet, exercise, and supplements has been shown to match the effect of modern disease-modifying therapies on preventing relapses and long-term disability. Most neurologists recommend lifestyle changes as a complement to medication, not a replacement.
Making the Decision
Living with MS without medication is possible, and some people will do relatively well for a long time. But the natural history data makes the gamble clear: without treatment, the majority of people with relapsing-remitting MS will eventually develop progressive disability, and there’s no reliable way to predict early on who will be the exception. The people who do well untreated at 10 years are not guaranteed to stay that way at 20.
If your hesitation about medication comes from side effects, cost, or the burden of treatment, those are legitimate concerns worth discussing with your neurologist. The range of available therapies is wider than ever, with different risk profiles, dosing schedules, and routes of administration. Some are daily pills, others are infusions given only once or twice a year. The conversation doesn’t have to be all or nothing.